COPD Assessment Test Can Predict Depression

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-12-31

Study Completion Date

2013-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The frequency of depression in COPD patients are substantial and early detection and prevention of depression is critical.

Recently, COPD assessment test (CAT) was developed and validated to assess the impact of COPD on patients' quality of life.

In this prospective study, we will investigate the predictive utility of CAT for predicting depression in COPD patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is aimed to investigate the association between the COPD Assessment Test (CAT) and depression in stable COPD patients. Stable COPD patients will be enrolled from the tertiary hospitals. All patients will undergo lung function tests. The Korean versions of the CAT (COPD assessment test) and Patient Health Questionnaire-9 (PHQ-9) will be used to assess COPD symptoms and depressive disorder, respectively.

We will compare the depresssion frequency among GOLD classifications of airway limitation and among the four CAT groups. And. we will also investigate which items of the CAT are the strongest indicators of depression.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression, COPD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* COPD patients who aged \> or = 40 years

Exclusion Criteria

* acute exacerbation within 3 months
* bronchial asthma or an increase in FEV1 of more than 12% of the predicted value with the use of 400 µg of albuterol.
* other lung diseases such as bronchiectasis, interstitial lung disease, and tuberculosis-destroyed lungs.
* who denied to consent.

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

KI-Suck Jung, Dr.

Role: PRINCIPAL_INVESTIGATOR

Hallym University Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hallym University Sacred Heart Hospital, Department of Pulmonary, Critical Care Medicine

Anyang-si, Gyeonggi-do, South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sunghoon Park, Dr.

Role: CONTACT

Phone: 82-31-380-3803

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sunghoon Park, MD

Role: primary

Sun Hyang Kim

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2011-I010

Identifier Type: -

Identifier Source: org_study_id